VIOLIN: Vaccine Investigation and Online Information Network

Vaccine Detail

MART-1:26-35(27L) Peptide Vaccine

Vaccine Information

Vaccine Name: MART-1:26-35(27L) Peptide Vaccine
Target Pathogen: Cancer
Target Disease: Cancer
Vaccine Ontology ID: VO_0007506
Type: Other
Status: Clinical trial
Host Species for Licensed Use: Human
Host Species as Laboratory Animal Model: Human
Antigen: MLANA
MLANA gene engineering:
- Type: Recombinant protein preparation
- Description: MLANA, also known as MART-1, was used as one vaccine antigen for the cancer vaccine (Keller et al., 2015).
- Detailed Gene Information: Click Here.
gp100 (PMEL) gene engineering:
- Type: Recombinant protein preparation
- Description: (Keller et al., 2015)
- Detailed Gene Information: Click Here.
Description: NULL

Host Response

References

Keller et al., 2015: Keller M, Ebstein F, Bürger E, Textoris-Taube K, Gorny X, Urban S, Zhao F, Dannenberg T, Sucker A, Keller C, Saveanu L, Krüger E, Rothkötter HJ, Dahlmann B, Henklein P, Voigt A, Kuckelkorn U, Paschen A, Kloetzel PM, Seifert U. The proteasome immunosubunits, PA28 and ER-aminopeptidase 1 protect melanoma cells from efficient MART-126-35 -specific T-cell recognition. European journal of immunology. 2015; 45(12); 3257-3268. [PubMed: 26399368].